logo
  • Pipeline
    • Research Pipeline
    • Paltusotine
    • CRN04894, Oral ACTH Antagonist
    • Oral PTH Antagonist
  • Patients
    • Clinical Trials
    • Expanded Access Policy
    • Letter to Acromegaly Community
    • Patient Videos
      • Clinical Trials
      • Acromegaly in a Pandemic
      • Acromegaly Symptoms
      • Acromegaly Diagnosis
      • Acromegaly Advocate
      • Acromegaly Support
  • Professionals
    • Acromegaly
    • Carcinoid Syndrome
  • Investors
    • Overview
    • Corporate Presentation
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Analyst Coverage
    • Investor Resources
    • Unmet Medical Need in Acromegaly
  • About Us
    • Meet Us
    • Employee Spotlight
    • Culture
    • Community
  • Careers
    • Culture
    • Job Listings
    • Benefits
  • Contact
    • Contact Us
    • Partnering
    • Grants and Funding
https://crinetics.com/wp-content/uploads/2022/01/crnx-homepage-full-optimized.mp4

Better therapies.
Better lives.

Pipeline >

Acromegaly in a Pandemic

Four patients discuss the challenges and anxieties of living with the rare disease,
acromegaly, in the COVID-19 pandemic.

Watch Our Video
acromegaly pandemic slide imag uai

A fuller, freer life is within reach.


Living with a rare endocrine disease can be challenging. We’re working on new treatments to these life-threatening conditions that you need and deserve. Like an oral treatment for acromegaly called paltusotine, which will be a welcome development for many patients and their families.

Read About Our Studies

A company as rare as the diseases
we focus on.


Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.

Learn More About Us

We've built a better workplace to help patients build better lives.


“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?

Explore Working Here

Better therapies.
Better lives.

Pipeline >

Acromegaly in a Pandemic

Four patients discuss the challenges and anxieties of living with the rare disease,
acromegaly, in the COVID-19 pandemic.

Watch Our Video
acromegaly pandemic slide imag uai

A fuller,
freer life is
within reach.


Living with a rare endocrine disease can be challenging. We’re working on new treatments to these life-threatening conditions that you need and deserve. Like an oral treatment for acromegaly called paltusotine, which will be a welcome development for many patients and their families.

Read About Our Studies

A company as rare as the diseases
we focus on.


Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.

Learn More About Us

We've built a better workplace to help patients build better lives.


“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?

Explore Working Here

Press Releases


crin home box pressrelease grey uai

Investor Relations


investor relations crinetics pharmaceuticals

News


crin home box news grey uai

[mc4wp_form id=”90356″]

Medical Education Grant Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA)
Type of Grant

Key Points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead

Investigator-Initiated Research Study Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA):

Key points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead